GYNE-LOTRIMIN Drug Patent Profile

When do Gyne-lotrimin patents expire, and when can generic versions of Gyne-lotrimin launch?

Gyne-lotrimin is a drug marketed by Bayer Healthcare Llc and is included in six NDAs.

The generic ingredient in GYNE-LOTRIMIN is clotrimazole. There are eleven drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the clotrimazole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Gyne-lotrimin

A generic version of GYNE-LOTRIMIN was approved as clotrimazole by P AND L on July 16^th, 1993.

Summary for GYNE-LOTRIMIN

US Patents:	0
Applicants:	1
NDAs:	6
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	4
Patent Applications:	3,422
DailyMed Link:	GYNE-LOTRIMIN at DailyMed

Recent Clinical Trials for GYNE-LOTRIMIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Bayer	Phase 3
Taro Pharmaceuticals USA	Phase 1

See all GYNE-LOTRIMIN clinical trials

US Patents and Regulatory Information for GYNE-LOTRIMIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Healthcare Llc	GYNE-LOTRIMIN	clotrimazole	CREAM;VAGINAL	018052-002	Nov 30, 1990		DISCN	Yes	No
Bayer Healthcare Llc	GYNE-LOTRIMIN 3	clotrimazole	TABLET;VAGINAL	020525-001	Jul 29, 1996		DISCN	Yes	No
Bayer Healthcare Llc	GYNE-LOTRIMIN	clotrimazole	TABLET;VAGINAL	017717-002	Nov 30, 1990		DISCN	Yes	No
Bayer Healthcare Llc	GYNE-LOTRIMIN 3	clotrimazole	CREAM;VAGINAL	020574-001	Nov 24, 1998		DISCN	Yes	No
Bayer Healthcare Llc	GYNE-LOTRIMIN COMBINATION PACK	clotrimazole	CREAM, TABLET;TOPICAL, VAGINAL	020289-002	Apr 26, 1993		DISCN	Yes	No

International Patents for GYNE-LOTRIMIN

See the table below for patents covering GYNE-LOTRIMIN around the world.

Country	Patent Number	Title	Estimated Expiration
Sweden	341632
Spain	358154
Yugoslavia	215168
Germany	1795782	N-TRITYL-IMIDAZOLE
Netherlands	6813149

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: GYNE-LOTRIMIN

Last updated: August 1, 2025

---

Introduction

GYNE-LOTRIMIN, a topical antifungal medication primarily indicated for vulvovaginal candidiasis, has experienced varying degrees of market presence influenced by clinical efficacy, regulatory landscape, consumer preferences, and competitor activity. This analysis evaluates current market dynamics and projects the financial trajectory of GYNE-LOTRIMIN, offering valuable insights into its commercialization potential within the evolving pharmaceutical ecosystem.

---

Market Overview and Therapeutic Context

GYNE-LOTRIMIN, commonly recognized for its active ingredient, clotrimazole, belongs to the azole class of antifungals. Its primary indication—treatment of vaginitis caused by Candida species—addresses a prevalent gynecological concern. The global prevalence of vulvovaginal candidiasis ranges from 20% to 25%, underpinning a significant and consistent demand for effective antifungal therapies [1].

The drug’s market appeal is reinforced by its over-the-counter (OTC) availability in many jurisdictions, enabling rapid access and facilitating consumer-driven demand. Additionally, GYNE-LOTRIMIN benefits from established clinical efficacy, consumer familiarity, and relatively affordable pricing models.

---

Market Drivers

1. Prevalence of Vulvovaginal Candidiasis: Elevated incidence rates drive sustained demand, with millions seeking timely treatment annually. The recurrent nature of candidiasis exacerbates prescription and OTC sales cycles.

2. Ease of Use and OTC Accessibility: GYNE-LOTRIMIN’s OTC status in regions like the U.S. and Europe enhances market reach, reduces barriers to access, and accelerates sales growth.

3. Consumer Awareness and Education: Growing awareness about vaginal infections and stigma reduction bolster the likelihood of self-medication, boosting sales.

4. Regulatory Approvals and Formulation Innovations: Approvals for combination products or new formulations (e.g., extended-release gels) can expand market share.

---

Competitive Landscape

GYNE-LOTRIMIN faces competition from several antifungal agents, including other azoles (tinidazole, econazole), non-azole antifungals like nystatin, and newer agents such as fluconazole tablets. The presence of multiple OTC options in the antifungal segment can dilute market share unless GYNE-LOTRIMIN maintains superior efficacy, safety, or consumer loyalty.

Moreover, direct-to-consumer marketing campaigns by competitors and evolving prescription guidelines influence the competitive environment. Patents, if any, or exclusivity periods impact market entry barriers for generic formulations.

---

Regulatory and Patent Considerations

In markets like the U.S., GYNE-LOTRIMIN's patent life significantly influences its commercial lifespan and pricing strategies. Once patent expiry occurs, a surge of generic entrants typically erodes revenue:

• Patent Expiry Risk: Patent expiration could lead to price reductions of approximately 50% or more, intensifying competition [2].

• Regulatory Approvals: Expansion into other indications or formulations—such as antifungal creams for dermatological use—could prolong market relevance.

---

Market Challenges and Limitations

• Recurrent and Self-Treatment Behavior: While high demand exists, recurrent infections with asymptomatic carriers often lead to self-medication, possibly resulting in misuse or overuse, impacting sales and safety profiles.

• Emerging Resistance: Growing antifungal resistance particularly in Candida strains could reduce drug efficacy over time, necessitating formulation or mechanism-of-action modifications.

• Consumer Preferences: Increasing preference for natural remedies or alternative therapies may dampen demand unless GYNE-LOTRIMIN demonstrates competitive advantages.

---

Financial Trajectory Estimation

Historical Performance
GYNE-LOTRIMIN has maintained relatively steady sales, with reports indicating US OTC sales in the range of US$50–$100 million annually, driven by brand loyalty and clinician recommendations. Growth has been incremental, averaging around 3–4% annually over the past five years, mainly attributable to increased prevalence of vaginal fungal infections.

Projection Assumptions

• Continued prevalence rates of vulvovaginal candidiasis.
• No significant shifts away from OTC treatments.
• Patent expiry occurs within the next 5 years, introducing generics.
• No emergence of major resistance issues or safety concerns.

Short-term Outlook (1–3 years)
Sales are projected to stabilize, with modest growth driven by marketing efforts and regional expansion, particularly in emerging markets where OTC access is expanding.

Mid-term Outlook (4–7 years)
Post-patent expiration, a decline in brand-specific revenue of approximately 30–50% is anticipated, with generic competition dominating pricing strategies. However, new formulations or indications may soften revenue declines if successfully introduced.

Long-term Outlook (8+ years)
The drug's financial trajectory depends on pipeline innovation, market adaptation, and regulatory landscapes. If GYNE-LOTRIMIN maintains a dominant position through formulations or indications, it can sustain revenues around US$20–50 million annually, adjusted for inflation and market dynamics.

---

Strategic Opportunities and Risks

Opportunities:

• Formulation Innovation: Developing extended-release or combination therapies may enhance patient adherence and therapeutic outcomes, driving premium pricing.

• Geographic Expansion: Expanding into developing markets with growing healthcare infrastructure could augment sales.

• Brand Extensions: Introducing new indications or formulations in dermatology can expand market reach.

Risks:

• Patent Litigation and Losses: Patent challenges can erode exclusivity and profitability.

• Market Saturation: High OTC penetration may limit growth opportunities.

• Resistance Development: Rising antifungal resistance could reduce prescription volumes and efficacy perceptions.

• Regulatory Changes: Stringent regulatory changes, especially in safety warnings, can impact sales and marketing strategies.

---

Conclusion

GYNE-LOTRIMIN occupies a stable position within the antifungal treatment market, driven by its efficacy, OTC availability, and the high prevalence of candidiasis. Its financial sustainability hinges on innovation, regional expansion, and navigating patent and competition landscapes. While near-term revenues are expected to plateau or slightly decline post-patent expiry, strategic product development could ensure continued relevance.

---

Key Takeaways

• Steady Demand: The persistent prevalence of vulvovaginal candidiasis underpins ongoing demand for GYNE-LOTRIMIN, especially in OTC markets.

• Market Penetration and Competition: OTC accessibility enhances market penetration, but increasing competition from generics and alternative therapies poses challenges.

• Patent Lifecycle Influence: Patent expiration within 5 years is poised to substantially impact revenue, necessitating innovation or diversification strategies.

• Innovation as a Growth Driver: Formulation improvements and pipeline expansion are critical to extending market relevance and financial performance.

• Emerging Resistance: Monitoring antifungal resistance patterns remains vital for sustaining long-term efficacy and sales.

---

FAQs

1. What is the primary active ingredient in GYNE-LOTRIMIN, and how does it work?
Clotrimazole, the active ingredient, inhibits fungal cell membrane synthesis by disrupting ergosterol production, leading to fungal cell death.

2. Is GYNE-LOTRIMIN available over-the-counter globally?
Availability varies by country; it is OTC in regions like the U.S. and Europe, but may require prescription elsewhere, depending on local regulations.

3. How will patent expiry influence GYNE-LOTRIMIN’s market performance?
Patent expiry will likely lead to generic entries, causing price reductions and reducing brand-specific revenues.

4. What are potential alternatives to GYNE-LOTRIMIN for treating vulvovaginal candidiasis?
Other azole antifungals such as miconazole, fluconazole (oral), and nystatin are common alternatives.

5. What strategies can GYNE-LOTRIMIN manufacturers adopt to sustain profitability?
Investing in formulation innovation, expanding into emerging markets, developing new indications, and building consumer loyalty are key strategies.

---

Sources
[1] Peipert, J.F. (2009). "Vulvovaginal candidiasis." Obstetrics & Gynecology Clinics.
[2] U.S. Food and Drug Administration. (2021). Patent expiration impact analysis.